Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis

Introduction. Currently, clinical trials of DMTs strive to determine their effect on neuroinflammation and neurodegeneration. We aimed to determine the impact of currently used DMTs on brain atrophy and disability in RRMS. The main goal of this review is to evaluate the neuroprotective potential of...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Multiple sclerosis international Ročník 2023; s. 1 - 11
Hlavní autori:	Chylińska, Magdalena, Komendziński, Jakub, Wyszomirski, Adam, Karaszewski, Bartosz
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	New York Hindawi 31.08.2023 John Wiley & Sons, Inc
Predmet:	Atrophy Automation Care and treatment Clinical trials Diagnostic imaging Inflammation Information processing Magnetic resonance imaging Methods Monoclonal antibodies Multiple sclerosis Nervous system Neurodegeneration Processing speed Review Shrinkage
ISSN:	2090-2654, 2090-2662
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!